Olaparib Tablets Prolong Progression-free Survival in Ovarian Cancer

Share this content:
Maintenance treatment with olaparib tablets may prolong PFS without negatively affecting quality of life among patients with relapsed ovarian cancer.
Maintenance treatment with olaparib tablets may prolong PFS without negatively affecting quality of life among patients with relapsed ovarian cancer.

Maintenance treatment with olaparib tablets may prolong progression-free survival (PFS) without negatively affecting quality of life among patients with relapsed ovarian cancer, according to a study published in The Lancet Oncology.1

For the phase 3 study SOLO2/ENGOT-Ov21 (ClinicalTrials.gov Identifier: NCT01874353), researchers enrolled 295 patients with relapsed ovarian cancer sensitive to platinum therapy who had received at least 2 lines of prior chemotherapy and who had a BRCA1/2 mutation. These patients were randomly assigned 2:1 to receive olaparib 300 mg tablets twice daily or placebo.

Study participants in the olaparib group had a significantly longer investigator-assessed PFS, with 19.1 months (95% CI, 16.3-25.7) with olaparib vs 5.5 months (95% CI, 5.2-5.8) for placebo (hazard ratio [HR], 0.30; 95% CI, 0.22-0.41; P < .0001).

Median time to first subsequent therapy was 27.9 months (95% CI, 22.6 to not calculable) in the olaparib group vs 7.1 months (95% CI, 6.3-8.3) for placebo. Median time to second progression was not reached in the olaparib arm vs 18.4 months (95% CI, 15.4-22.8) in the placebo arm. Median time to second subsequent therapy was not reached in the olaparib arm vs 18.2 months (95% CI, 15.0-20.5) in the placebo arm.

The most frequently reported grade 3 or worse adverse events (AEs) were anemia (19% olaparib vs 2% placebo), asthenia or fatigue (4% vs 2%), and neutropenia (5% vs 4%).

One patient in the olaparib arm developed treatment-related acute myeloid leukemia, which led to death.

RELATED: Tamoxifen or Exemestane With Ovarian Function Suppression Prolongs Breast Cancer-free Interval

The authors concluded that “olaparib can achieve a significant prolongation of progression-free survival in this patient population with no appreciable detrimental effect observed for patients' quality of life.”

Reference

  1. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul 25. doi: 10.1016/S1470-2045(17)30469-2 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters